Author/Authors :
Mahdavynia, Soheila Consultant Pediatric Nephrology - Iran University of Medical Sciences - Tehran, Iran , Hooman, Nakysa Consultant Pediatric Nephrology - Ali-Asghar Clinical Research Development Center - Iran University of Medical Sciences - Tehran, Iran , Otukesh, Hasan Consultant Pediatric Nephrology - Ali-Asghar Clinical Research Development Center - Iran University of Medical Sciences - Tehran, Iran , Hoseini-Shamsabadi, Rozita Consultant Pediatric Nephrology - Ali-Asghar Clinical Research Development Center - Iran University of Medical Sciences - Tehran, Iran , Nickavar, Azar Consultant Pediatric Nephrology - Ali-Asghar Clinical Research Development Center - Iran University of Medical Sciences - Tehran, Iran
Abstract :
Atypical hemolytic uremic syndrome (HUS) is defined as a heterogeneous group of disorders. Plasma infusion or plasma exchange is the rescue therapy for this life-threatening syndrome. There is no evidence for the volume of plasma required to induce remission. Materials and Methods: Between 2007 and 2018, Forty – two patients (M=20, F=22) with a diagnosis of recurrent or familial atypical hemolytic uremic syndrome (aHUS) who were admitted to Ali-Asgar Children’s Hospital were enrolled in this observational retrospective study. The total volume of plasma required for normalizing platelet (>150000) and LDH (<500 IU), eliminating hemolysis, and decreasing serum creatinine at first presentation of disease was calculated. Patients with TTP, vasculitis, and post infectious HUS were excluded. Results: The mean age of the patients was 53 months (3-144 m). The majority of patients achieved remission at first presentation by plasma infusion (5 under peritoneal dialysis and 4 under hemodialysis) but ten patients required plasmapheresis. A total of 980 units of FFP perfused with a total volume of 195.975 L. The median (range) total plasma volume required for remission was 166 ml/kg (43-2850 ml/kg).
Conclusions: This study showed that the required plasma volume for the acute phase of atypical HUS for controlling the first attack of disease.